Management Team

Benjamin Belinka, Ph.D.

Belinka
The President and CEO of Actinobac Biomed is Dr. Benjamin Belinka. Dr. Belinka obtained his Ph.D. in chemistry from State University of NY at Binghamton and has over 28 years of experience in the pharmaceutical and biotechnology industry as both a scientist and executive. Beginning his career at Sandoz Pharmaceuticals (now Novartis) in 1981, where he supervised process research and development laboratories in both the United States and Switzerland, Dr. Belinka extensively participated in all aspects of the preclinical development of a number of drug candidates designed to combat a variety of disease indications. After moving to Cytogen Corporation six years later, Dr. Belinka, as Assistant Director of Preclinical Research & Chemistry, managed research laboratories and supported the advancement of the company’s diagnostic and bone pain agents through preclinical and clinical development. Joining VectraMed, Inc. in 1998 as its Director of Chemistry and later as Vice President, Dr. Belinka was responsible for designing the company’s proprietary drug delivery technology, organizing and setting up its research facilities, and negotiating cooperative research programs with major pharmaceutical organizations such as (Elan, Pfizer, Ethicon, & Aventis) providing over $7 million in revenue. Dr. Belinka has more than a dozen scientific publications and abstracts and 15 patents.


Scott C. Kachlany, Ph.D.

Kachlany
Dr. Scott Kachlany is the Founder and Chief Scientific Officer of Actinobac Biomed, Inc., He is also an Associate Professor of Oral Biology and Microbiology at Rutgers School of Dental Medicine at the Biomedical Health Sciences Campus in Newark, NJ. Dr. Kachlany obtained his B.S. degree from Cornell University in Ithaca, NY in 1997 and Ph.D. from Columbia University College of Physicians and Surgeons in 2001. Dr. Kachlany has published more than 40 scientific articles and is recipient of numerous awards and honors; most recently the 2013 Thomas Edison Patent of the Year Award and 2013 New Jersey Inventors Hall of Fame Innovators Award.


Hematologic Diseases

Hematologic diseases (leukemia, lymphoma, and multiple myeloma) are cancers of white blood cells that are often deadly and difficult to treat. Preclinical efficacy studies have shown that Leukothera™ is highly effective at eliminating malignant white blood cells both under laboratory conditions and in animals.

Read More

Autoimmune Diseases

Autoimmune and inflammatory diseases comprise a range of disorders that are characterized by the abundant presence of chronically activated WBCs. Leukothera® specifically targets these activated WBCs without affecting healthy cells and tissues.

Read More

HIV

HIV infects white blood cells and can hide from our immune system within them. Current therapies can target replicating virus, but do not eliminate the HIV-infected cells. These infected white blood cells are what prevent any current drugs from curing HIV infection.

Read More